EAN 2026 | Detecting and disrupting disability accumulation in MS: a session at EAN 2026

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, shares insights from a session at EAN 2026 on detecting and disrupting disability accumulation in multiple sclerosis (MS). Although advances in anti-inflammatory therapies have significantly improved disease management, Dr Oreja-Guevara explains that many patients continue to experience disability progression. She discusses the need for next-generation treatments that target microglial activation, with the aim of slowing or preventing progression. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.